<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Affect Disord</journal-id><journal-id journal-id-type="iso-abbrev">J Affect Disord</journal-id><journal-title-group><journal-title>Journal of Affective Disorders</journal-title></journal-title-group><issn pub-type="ppub">0165-0327</issn><issn pub-type="epub">1573-2517</issn><publisher><publisher-name>Published by Elsevier B.V.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">36907459</article-id><article-id pub-id-type="pmc">PMC10005840</article-id><article-id pub-id-type="pii">S0165-0327(23)00353-1</article-id><article-id pub-id-type="doi">10.1016/j.jad.2023.03.019</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Stress levels, psychological symptoms, and C-reactive protein levels in COVID-19: A cross-sectional study</article-title></title-group><contrib-group><contrib contrib-type="author" id="au0005"><name><surname>de Azevedo Cardoso</surname><given-names>Taiane</given-names></name><xref rid="af0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au0010"><name><surname>Silva</surname><given-names>Ritele H.</given-names></name><xref rid="af0010" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au0015"><name><surname>Fernandes</surname><given-names>Jessica L.</given-names></name><xref rid="af0010" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au0020"><name><surname>Arent</surname><given-names>Camila O.</given-names></name><xref rid="af0010" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au0025"><name><surname>Amboni</surname><given-names>Graziela</given-names></name><xref rid="af0010" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au0030"><name><surname>Borba</surname><given-names>Laura A.</given-names></name><xref rid="af0010" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au0035"><name><surname>Padilha</surname><given-names>Alex Paulo Z.</given-names></name><xref rid="af0010" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au0040"><name><surname>Botelho</surname><given-names>Maria Eduarda M.</given-names></name><xref rid="af0010" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au0045"><name><surname>Maciel</surname><given-names>Amanda L.</given-names></name><xref rid="af0010" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au0050"><name><surname>Barichello</surname><given-names>Tatiana</given-names></name><xref rid="af0015" ref-type="aff">c</xref><xref rid="af0020" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="au0055"><name><surname>Morales</surname><given-names>Rodrigo</given-names></name><xref rid="af0025" ref-type="aff">e</xref><xref rid="af0030" ref-type="aff">f</xref></contrib><contrib contrib-type="author" id="au0060"><name><surname>Soares</surname><given-names>Silvio Jos&#x000e9; B.</given-names></name><xref rid="af0035" ref-type="aff">g</xref></contrib><contrib contrib-type="author" id="au0065"><name><surname>Bagatini</surname><given-names>Margarete D.</given-names></name><xref rid="af0035" ref-type="aff">g</xref></contrib><contrib contrib-type="author" id="au0070"><name><surname>Dallagnol</surname><given-names>Claudia</given-names></name><xref rid="af0035" ref-type="aff">g</xref></contrib><contrib contrib-type="author" id="au0075"><name><surname>Brighenti</surname><given-names>Marta Elisa</given-names></name><xref rid="af0035" ref-type="aff">g</xref></contrib><contrib contrib-type="author" id="au0080"><name><surname>Ign&#x000e1;cio</surname><given-names>Zuleide Maria</given-names></name><xref rid="af0035" ref-type="aff">g</xref></contrib><contrib contrib-type="author" id="au0085"><name><surname>Quevedo</surname><given-names>Jo&#x000e3;o</given-names></name><xref rid="af0010" ref-type="aff">b</xref><xref rid="af0020" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="au0090"><name><surname>Ceretta</surname><given-names>Luciane B.</given-names></name><xref rid="af0040" ref-type="aff">h</xref></contrib><contrib contrib-type="author" id="au0095"><name><surname>R&#x000e9;us</surname><given-names>Gislaine Z.</given-names></name><xref rid="af0010" ref-type="aff">b</xref><xref rid="cr0005" ref-type="corresp">&#x0204e;</xref></contrib><aff id="af0005"><label>a</label>Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON, Canada</aff><aff id="af0010"><label>b</label>Translational Psychiatry Laboratory, Graduate Program in Health Sciences, University of Southern Santa Catarina (UNESC), Crici&#x000fa;ma, SC, Brazil</aff><aff id="af0015"><label>c</label>Graduate Program in Health Sciences, University of Southern Santa Catarina (UNESC), Crici&#x000fa;ma, SC, Brazil</aff><aff id="af0020"><label>d</label>Center of Excellence on Mood Disorders, Faillace Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth), Houston, TX, USA</aff><aff id="af0025"><label>e</label>Department of Neurology, McGovern Medical School, UTHealth, Houston, TX, USA</aff><aff id="af0030"><label>f</label>Centro Integrativo de Biolog&#x000ed;a y Qu&#x000ed;mica Aplicada (CIBQA), Universidad Bernardo O'Higgins, Santiago, Chile</aff><aff id="af0035"><label>g</label>Laboratory of Physiology Pharmacology and Psychopathology, Graduate Program in Biomedical Sciences, Federal University of the Southern Frontier, Chapec&#x000f3;, SC, Brazil</aff><aff id="af0040"><label>h</label>Graduate Program in Public Health, University of Southern Santa Catarina (UNESC), Crici&#x000fa;ma, SC, Brazil</aff></contrib-group><author-notes><corresp id="cr0005"><label>&#x0204e;</label>Corresponding author at: Translational Psychiatry Laboratory, University of Southern Santa Catarina, Criciuma, SC 88806-000, Brazil.</corresp></author-notes><pub-date pub-type="pmc-release"><day>11</day><month>3</month><year>2023</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="ppub"><day>1</day><month>6</month><year>2023</year></pub-date><pub-date pub-type="epub"><day>11</day><month>3</month><year>2023</year></pub-date><volume>330</volume><fpage>216</fpage><lpage>226</lpage><history><date date-type="received"><day>12</day><month>9</month><year>2022</year></date><date date-type="rev-recd"><day>28</day><month>2</month><year>2023</year></date><date date-type="accepted"><day>7</day><month>3</month><year>2023</year></date></history><permissions><copyright-statement>&#x000a9; 2023 Published by Elsevier B.V.</copyright-statement><copyright-year>2023</copyright-year><copyright-holder/><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><abstract id="ab0005"><sec><title>Background</title><p>Although many studies have pointed out a possible relationship between COVID-19 and the presence of psychiatric disorders, the majority of the studies have significant limitations. This study investigates the influence of COVID-19 infection on mental health.</p></sec><sec><title>Methods</title><p>This cross-sectional study included an age- and sex-matched sample of adult individuals positive (cases) or negative (controls) for COVID-19. We evaluated the presence of psychiatric conditions and C-reactive protein (CRP).</p></sec><sec><title>Results</title><p>Findings showed greater severity of depressive symptoms, higher levels of stress, and greater CRP in cases. The severity of depressive and insomnia symptoms, as well as the CRP were more remarkable in individuals with moderate/severe COVID-19. We found a positive correlation between stress and severity of anxiety, depression, and insomnia in individuals with or without COVID-19. There was a positive correlation between CRP levels and severity of depressive symptoms in cases and controls, and a positive correlation between CRP levels and the severity of anxiety symptoms and stress levels only in individuals with COVID-19. Individuals with COVID-19 and depression had greater CRP than those with COVID-19 without current major depressive disorder.</p></sec><sec><title>Limitations</title><p>We cannot infer causality because this is a cross-sectional study, and the majority of COVID-19 sample was asymptomatic or had mild symptoms, which may limit the generalizability of our findings for moderate/severe cases.</p></sec><sec><title>Conclusions</title><p>Individuals with COVID-19 showed greater severity of psychological symptoms, which may impact on the development of psychiatric disorders in the future. CPR seem to be a promising biomarker for earlier detection of post-COVID depression.</p></sec></abstract><kwd-group id="ks0005"><title>Keywords</title><kwd>Stress</kwd><kwd>Anxiety</kwd><kwd>Major depressive disorder</kwd><kwd>Inflammation</kwd><kwd>C-reactive protein</kwd><kwd>COVID-19</kwd></kwd-group></article-meta></front><body><sec id="s0005"><label>1</label><title>Introduction</title><p id="p0030">Since its emergence in December 2019, coronavirus disease 2019 (COVID-19) has impacted all parts of the world, leading to serious public health problems, crippling health systems, causing thousands of deaths, and severe economic problems (<xref rid="bb0175" ref-type="bibr">World Health Organization, 2020a</xref>, <xref rid="bb0180" ref-type="bibr">World Health Organization, 2020b</xref>). The most frequent clinical presentation of severe COVID-19 is pneumonia with fever, dyspnea, and cough (<xref rid="bb0180" ref-type="bibr">World Health Organization, 2020b</xref>). In mild to moderate cases, individuals may have pneumonia without signs or symptoms of gravity (<xref rid="bb0180" ref-type="bibr">World Health Organization, 2020b</xref>).</p><p id="p0035">COVID-19 was firstly considered a respiratory system disease. However, it is well known that COVID-19 has more potential to invade other parts of the human body, including the cardiac, digestive, and renal systems (<xref rid="bb0110" ref-type="bibr">Manosso et al., 2021</xref>; <xref rid="bb0135" ref-type="bibr">Puelles et al., 2020</xref>). Although not still fully elucidated, it is known that COVID-19, as well as the virus that causes the disease, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), may have direct and indirect impacts on the central nervous system (CNS) (<xref rid="bb0145" ref-type="bibr">Song et al., 2021</xref>). Indeed, human and rodent studies demonstrated that SARS-CoV-2 has a neuroinvasive capacity associated with increased mortality rates (<xref rid="bb0145" ref-type="bibr">Song et al., 2021</xref>). More recently, a neuroimaging study revealed abnormalities in limbic brain regions associated with the olfactory network in individuals who had COVID-19 (<xref rid="bb0035" ref-type="bibr">Douaud et al., 2022</xref>). However, it is unclear whether these abnormal changes are a spreading hallmark of the virus in the brain or the pathogenic effects of the disease (<xref rid="bb0035" ref-type="bibr">Douaud et al., 2022</xref>).</p><p id="p0040">Neurological symptoms such as headaches and cognitive impairment, as well as a relationship between the COVID-19 pandemic and psychiatric disorders, have been pointed out by several studies (<xref rid="bb0040" ref-type="bibr">Grolli et al., 2021</xref>; <xref rid="bb0060" ref-type="bibr">He et al., 2021</xref>; <xref rid="bb0120" ref-type="bibr">Misra et al., 2021</xref>; <xref rid="bb0155" ref-type="bibr">Tchounwou et al., 2022</xref>; <xref rid="bb0185" ref-type="bibr">Yan et al., 2022</xref>). However, few studies have investigated if COVID-19 infection is associated with increased rates of psychiatric conditions, and sleep disorders.</p><p id="p0045">Some individuals infected by SARS-CoV-2 display excessive production of proinflammatory cytokines. This excessive immune response has been associated with COVID-19 severity and death (<xref rid="bb0020" ref-type="bibr">da Silva et al., 2022</xref>; <xref rid="bb0165" ref-type="bibr">del Valle et al., 2020</xref>; <xref rid="bb0200" ref-type="bibr">Zhang et al., 2020</xref>). Elevated levels of peripheral inflammatory markers, including proinflammatory cytokines and C-reactive protein (CRP), can also disrupt the blood-brain barrier, impact brain functions, and be associated with developing psychiatric conditions (<xref rid="bb0015" ref-type="bibr">Carlessi et al., 2021</xref>; <xref rid="bb0085" ref-type="bibr">Kuhlmann et al., 2009</xref>).</p><p id="p0050">In both COVID-19 infection and mood disorder, such as depression and anxiety, CRP concentrations are elevated (<xref rid="bb0075" ref-type="bibr">Iglesias-Gonz&#x000e1;lez et al., 2022</xref>; <xref rid="bb0095" ref-type="bibr">Liukkonen et al., 2011</xref>; <xref rid="bb0125" ref-type="bibr">Morales-Mu&#x000f1;oz et al., 2022</xref>). CRP may increase proinflammatory cytokines and impact brain inflammatory milieu and functions (<xref rid="bb0160" ref-type="bibr">Upthegrove and Khandaker, 2020</xref>). Indeed, a high risk of white matter abnormalities in COVID-19 encephalopathy patients was associated with elevated peripheral CRP levels (<xref rid="bb0140" ref-type="bibr">Rhally et al., 2021</xref>). In addition, elevated CRP concentrations are linked with COVID-19 severity (<xref rid="bb0150" ref-type="bibr">Song et al., 2020</xref>; <xref rid="bb0170" ref-type="bibr">Wang et al., 2020</xref>). Although some studies suggest a direct relationship between post-COVID-19 depression and CRP levels, other reports have communicated opposite outcomes (<xref rid="bb0045" ref-type="bibr">Guo et al., 2020</xref>; <xref rid="bb0115" ref-type="bibr">Mazza et al., 2021</xref>; <xref rid="bb0190" ref-type="bibr">Yuan et al., 2020</xref>). Thus, CRP effectiveness as a marker of post-COVID mood disorders requires further investigation (<xref rid="bb0100" ref-type="bibr">Lorkiewicz and Waszkiewicz, 2021</xref>).</p><p id="p0055">The pathophysiological mechanisms involved in developing neurological complications or psychiatric disorders arising or accentuating COVID-19 are complex and not fully comprehended (<xref rid="bb0025" ref-type="bibr">da Silva Lopes et al., 2021</xref>; <xref rid="bb0130" ref-type="bibr">Pezzini and Padovani, 2020</xref>; <xref rid="bb0205" ref-type="bibr">Zubair et al., 2020</xref>). Understanding the early diagnosis of psychiatric disorders is critical for better prognosis in COVID-19 patients, improving knowledge, and providing treatment targets. Although many studies have pointed out a possible relationship between COVID-19 and the presence of depression and anxiety, such studies have significant limitations, such as not having a control group of individuals without COVID-19 (<xref rid="bb0080" ref-type="bibr">Klaser et al., 2021</xref>) or reporting the presence of psychiatric conditions through self-reported tools (<xref rid="bb0190" ref-type="bibr">Yuan et al., 2020</xref>). Thus, our study aimed to investigate the impact of COVID-19 on stress levels, as well as on depression, anxiety, and sleep symptoms, comparing COVID-19-positive individuals with healthy controls. In addition, CRP concentrations were also investigated and correlated with psychological symptoms.</p></sec><sec id="s0010"><label>2</label><title>Methods and material</title><sec id="s0015"><label>2.1</label><title>Study design</title><p id="p0060">This cross-sectional study includes an age- and sex-matched sample of individuals with COVID-19 infection (cases) and individuals without COVID-19 infection (controls).</p></sec><sec id="s0020"><label>2.2</label><title>Setting</title><p id="p0065">The recruitment of participants took place between September 2020 and July 2021 at two sites: (1) <italic>Universidade do Extremo Sul Catarinense</italic> (UNESC, Crici&#x000fa;ma, Brazil) and (2) <italic>Universidade Federal da Fronteira Sul</italic> (UFFS, Chapec&#x000f3;, Brasil). The ethics committee board approved the study in both institutions under protocol numbers 4.172.382 and 4.298.662, respectively.</p></sec><sec id="s0025"><label>2.3</label><title>Study participants</title><p id="p0070">Cases were previously identified by the health authority departments in both two cities of southern Brazil (Chapec&#x000f3; and Criciuma) and were referred to the study. Then, the study team contacted the individuals to assess their eligibility. In addition, the recruitment of participants also occurred through social media advertisements. For the cases group, the inclusion criteria were (1) being aged between 18 and 90&#x000a0;years, (2) having the diagnosis of COVID-19 confirmed four to six weeks before study inclusion, and (3) living in Southern Brazil. The exclusion criteria were: (1) having the diagnosis of Bipolar Disorder and (2) presenting a physical or cognitive condition that precluded the individual from participating in the study (i.e., individuals that could not understand the questionnaires).</p><p id="p0075">The controls were recruited within the respective neighborhoods of the cases included. This strategy was adopted in order to recruit controls as similar as possible to the cases in terms of sociodemographic characteristics. The inclusion criteria for the controls were: (1) being aged between 18 and 90&#x000a0;years, (2) having a negative result in the rapid test for COVID-19 infection, and (3) living in Southern Brazil. The exclusion criteria were: (1) having the diagnosis of Bipolar Disorder and (2) presenting a physical or cognitive condition that precluded the individual from participating in the study (i.e., individuals that could not understand the questionnaires). Both controls or case individuals included did not receive vaccine for COVID-19 during the study period.</p></sec><sec id="s0030"><label>2.4</label><title>Demographics and psychiatric assessments</title><p id="p0080">The study assessments included different parameters, including sex, age, and years of education. In addition, individuals with COVID-19 answered questions about the severity of the COVID-19 symptoms they experienced and the use of medications for COVID-19.</p><p id="p0085">The outcomes investigated in this study were: (1) the diagnosis of current major depressive disorder (MDD), current anxiety disorders (panic disorder, agoraphobia, social anxiety, specific phobia, generalized anxiety disorder, obsessive-compulsive disorder, and posttraumatic stress disorder), (2) current suicide risk, (3) severity of anxiety, depressive, and insomnia symptoms, and (4) levels of stress.</p><p id="p0090">The diagnoses of current MDD, anxiety disorder, and suicide risk were assessed using the MINI International Neuropsychiatric Interview (MINI-Plus), a structured clinical interview based on DSM-IV criteria (<xref rid="bb0005" ref-type="bibr">Amorim, 2000</xref>). Trained health professionals administered the interview.</p><p id="p0095">The severity of depressive symptoms was assessed using the Hamilton Rating Scale for Depression (HAM&#x02014;D). The instrument consists of 17 questions quantitatively classified according to the severity of symptoms; the total score creates a discrete variable, where higher scores indicate greater severity (<xref rid="bb0050" ref-type="bibr">Hamilton, 1967</xref>). The severity of insomnia was assessed using items four, five, and six of the HAM&#x02014;D, which assess initial, intermediate, and late insomnia, respectively. We sum the three items, creating a discrete variable where higher scores indicate greater severity. The severity of anxiety symptoms was assessed using the Hamilton Anxiety Rating Scale (HAM-A), which is comprised of 14 items. Each item is scored according to its intensity; the total score is the sum of points assigned for all items ranging from 0 to 56. Higher total scores indicate greater severity of symptoms (<xref rid="bb0055" ref-type="bibr">Hamilton, 1959</xref>). Trained psychologists administered both scales (HAM-D and HAM-A).</p><p id="p0100">The levels of stress were assessed using the inventory of stress symptoms. The inventory consisted of an adaptation, with items obtained from the Checklist-90-R Symptom Inventory (SCL-90-R)(<xref rid="bb0030" ref-type="bibr">Derogatis, 1994</xref>). The SCL-90-R comprises 90 items, of which 24 were elected, with a score ranging from zero to five points in each item (<xref rid="bb0010" ref-type="bibr">Bertollo et al., 2020</xref>). Items that express stress symptoms were chosen and comparing them with stress items of SCL-90-R (<xref rid="bb0090" ref-type="bibr">Lipp and Guevara, 1994</xref>). The items identified are related to anxiety, depression, hostilities, and somatization symptoms but are not attributed only to a psychiatric disorder. The SCL-90-R was chosen because it is practical, easy to administer, and used for psychological assessment in individuals with several pathologies and assessed at the general clinic (<xref rid="bb0065" ref-type="bibr">Henna and Zilbernan, 2016</xref>).</p></sec><sec id="s0035"><label>2.5</label><title>Blood samples collection and CRP analysis</title><p id="p0105">Six milliliters of blood were withdrawn from each subject by venipuncture into a free-anticoagulant tube to obtain serum and 4&#x000a0;mL of peripheral venous blood in a tube with EDTA anticoagulant to obtain plasma. The blood was centrifuged at 3000 RPM for 10&#x000a0;min, and 10&#x000a0;&#x003bc;L of serum was used immediately for the SARS-CoV-2 rapid antibody test (colloidal gold immunochromatography) following the fabricant instructions (Leccurate, Lepu Technology) and 1.5&#x000a0;mL were aliquoted and kept frozen at &#x02212;80&#x000a0;&#x000b0;C until CRP analysis. EDTA plasma samples were sent to a support laboratory, and CRP levels were measured using an ultrasensitive immunoturbidimetric CRP assay.</p></sec><sec id="s0040"><label>2.6</label><title>Statistical analyses</title><p id="p0110">The statistical analyses were conducted using the SPSS 21. We tested the normality of the continuous variables using the Shapiro Wilk Test, and all the continuous variables presented a non-normal distribution. Then, the continuous data were presented as a median and interquartile range (IQR), and the comparison between groups was tested using the Mann-Whitney <italic>U</italic> test. The absolute and relative frequency data were compared using the chi-squared test. Spearman correlation was used to test the association between two continuous variables. The graphs were created using Graph Pad Prism 6.0.</p></sec></sec><sec id="s0045"><label>3</label><title>Results</title><sec id="s0050"><label>3.1</label><title>Sample characteristics</title><p id="p0115">This study included 350 individuals (114 cases with positive COVID-19 and 236 controls with negative COVID-19 tests confirmed four to six weeks before study inclusion). The sample characteristics are described in <xref rid="t0005" ref-type="table">Table 1</xref>. The proportion of female was 66.5&#x000a0;% (<italic>n</italic>&#x000a0;=&#x000a0;157) in the control group, and 64.9&#x000a0;% (<italic>n</italic>&#x000a0;=&#x000a0;74) in the case group (<italic>p</italic>&#x000a0;=&#x000a0;0.765). The median of age was 35.00 (IQR: 25.25&#x02013;47.00) in the control group, and 39.00 (IQR: 28.00&#x02013;52.50, <italic>p</italic>&#x000a0;=&#x000a0;0.085) in the case group. The median of years of education was 16.00 (IQR: 12.00&#x02013;18.00) in the control group, and 15.00 (IQR: 11.00&#x02013;19.00, <italic>p</italic>&#x000a0;=&#x000a0;0.349) in the case group. Thus, there was no difference between cases and controls regarding sex, age, and years of education. In individuals with COVID-19, the majority presented with mild disease manifestation (68.8&#x000a0;%) and reported using medication to treat COVID-19 and symptoms (83.3&#x000a0;%) (<xref rid="t0005" ref-type="table">Table 1</xref>). Among individuals with COVID-19 that reported using medication to treat COVID-19 and symptoms (<italic>n</italic>&#x000a0;=&#x000a0;95), the most commonly used medications were: paracetamol/dipyrone (58.7&#x000a0;%, <italic>n</italic>&#x000a0;=&#x000a0;54), azithromycin (53.3&#x000a0;%, <italic>n</italic>&#x000a0;=&#x000a0;49), ivermectin (19.8&#x000a0;%, <italic>n</italic>&#x000a0;=&#x000a0;18), vitamin C (20.9&#x000a0;%, <italic>n</italic>&#x000a0;=&#x000a0;19), vitamin D (18.7&#x000a0;%, <italic>n</italic>&#x000a0;=&#x000a0;17), prednisone (17.6&#x000a0;%, <italic>n</italic>&#x000a0;=&#x000a0;16), zinc (17.4&#x000a0;%, n&#x000a0;=&#x000a0;16), ibuprofen (15.4&#x000a0;%, <italic>n</italic>&#x000a0;=&#x000a0;14), and dexamethasone (14.3&#x000a0;%, <italic>n</italic>&#x000a0;=&#x000a0;13). More details about the use of medication can be found in the supplementary material (<xref rid="ec0005" ref-type="supplementary-material">Table S1</xref>).</p></sec><sec id="s0055"><label>3.2</label><title>Presence of psychiatric diagnosis in individuals with COVID-19</title><p id="p0125"><xref rid="t0010" ref-type="table">Table 2</xref> shows the proportion of psychiatric diagnoses between cases and controls. Although individuals with COVID-19 had a greater proportion of current MDD (14.9&#x000a0;%) and current anxiety disorders (38.6&#x000a0;%) as compared to controls (11.0&#x000a0;% for current MDD and 30.5&#x000a0;% for current anxiety disorders), this difference was not statistically significant (<italic>p</italic>&#x000a0;=&#x000a0;0.298 for current MDD, and <italic>p</italic>&#x000a0;=&#x000a0;0.132 for current anxiety disorders). The proportion of current suicide risk was similar between cases (13.2&#x000a0;%) and controls (12.3&#x000a0;%, <italic>p</italic>&#x000a0;=&#x000a0;0.818). (<xref rid="t0010" ref-type="table">Table 2</xref>).<table-wrap position="float" id="t0005"><label>Table 1</label><caption><p>Sociodemographic characteristics between groups and clinical characteristics for individuals with COVID-19.</p></caption><alt-text id="al0055">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th/><th>Control COVID-19 negative <italic>n</italic>&#x000a0;=&#x000a0;236</th><th>Case COVID-19 positive <italic>n</italic>&#x000a0;=&#x000a0;114</th><th><italic>p</italic>-Value</th></tr></thead><tbody><tr><td colspan="4">Sex<xref rid="tf0005" ref-type="table-fn">&#x0204e;</xref></td></tr><tr><td>Female</td><td>157 (66.5&#x000a0;%)</td><td>74 (64.9&#x000a0;%)</td><td rowspan="2">0.765</td></tr><tr><td>Male</td><td>79 (33.5&#x000a0;%)</td><td>40 (35.1&#x000a0;%)</td></tr><tr><td>Age<xref rid="tf0010" ref-type="table-fn">&#x0204e;&#x0204e;</xref>, <xref rid="tf0015" ref-type="table-fn">#</xref></td><td>35.00 (25.25&#x02013;47.00)</td><td>39.00 (28.00&#x02013;52.50)</td><td>0.085</td></tr><tr><td>Years of education<xref rid="tf0010" ref-type="table-fn">&#x0204e;&#x0204e;</xref>, <xref rid="tf0020" ref-type="table-fn">+</xref></td><td>16.00 (12.00&#x02013;18.00)</td><td>15.00 (11.00&#x02013;19.00)</td><td>0.349</td></tr><tr><td colspan="4">&#x02028;&#x02028;</td></tr><tr><td colspan="4">Severity of COVID-19 symptoms<xref rid="tf0025" ref-type="table-fn">##</xref></td></tr><tr><td>Asymptomatic</td><td>&#x02013;</td><td>12 (10.7&#x000a0;%)</td><td rowspan="4">&#x02013;</td></tr><tr><td>Mild symptoms</td><td>&#x02013;</td><td>77 (68.8&#x000a0;%)</td></tr><tr><td>Moderate symptoms</td><td>&#x02013;</td><td>20 (17.9&#x000a0;%)</td></tr><tr><td>Severe symptoms</td><td>&#x02013;</td><td>3 (2.7&#x000a0;%)</td></tr><tr><td colspan="4">&#x02028;&#x02028;</td></tr><tr><td colspan="4">Use of medication for COVID-19<xref rid="tf0030" ref-type="table-fn">++</xref></td></tr><tr><td>No</td><td>163 (70.9&#x000a0;%)</td><td>19 (16.7&#x000a0;%)</td><td rowspan="2">&#x0003c;0.001</td></tr><tr><td>Yes</td><td>67 (29.1&#x000a0;%)</td><td>95 (83.3&#x000a0;%)</td></tr></tbody></table><table-wrap-foot><fn><p>Legend:</p></fn></table-wrap-foot><table-wrap-foot><fn id="tf0005"><label>&#x0204e;</label><p id="np0005">Data is shown as absolute (n) and relative (%).</p></fn></table-wrap-foot><table-wrap-foot><fn id="tf0010"><label>&#x0204e;&#x0204e;</label><p id="np0010">Data shown as median and interquartile range.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tf0015"><label>#</label><p id="np0015">Variable contains one missing data in the case group.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tf0020"><label>+</label><p id="np0020">Variable contains seven missing data in the control group and three missing data in the case group.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tf0025"><label>##</label><p id="np0025">Variable contains two missing data in the case group.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tf0030"><label>++</label><p id="np0030">Variable contains six missing data in the control group.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="t0010"><label>Table 2</label><caption><p>Psychiatric diagnosis between the groups.</p></caption><alt-text id="al0060">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th/><th>Control COVID-19 negative n&#x000a0;=&#x000a0;236</th><th>Case COVID-19 positive n&#x000a0;=&#x000a0;114</th><th>p-Value</th></tr></thead><tbody><tr><td colspan="4">Current MDD episode <xref rid="tf0035" ref-type="table-fn">&#x0204e;</xref></td></tr><tr><td>No</td><td>210 (89.0&#x000a0;%)</td><td>97 (85.1&#x000a0;%)</td><td align="char" rowspan="2">0.298</td></tr><tr><td>Yes</td><td>26 (11.0&#x000a0;%)</td><td>17 (14.9&#x000a0;%)</td></tr><tr><td colspan="4">&#x02028;&#x02028;</td></tr><tr><td colspan="4">Current suicide risk<xref rid="tf0035" ref-type="table-fn">&#x0204e;</xref></td></tr><tr><td>No</td><td>207 (87.7&#x000a0;%)</td><td>99 (86.8&#x000a0;%)</td><td align="char" rowspan="2">0.818</td></tr><tr><td>Yes</td><td>29 (12.3&#x000a0;%)</td><td>15 (13.2&#x000a0;%)</td></tr><tr><td colspan="4">&#x02028;&#x02028;</td></tr><tr><td colspan="4">Current anxiety</td></tr><tr><td>Disorder<xref rid="tf0035" ref-type="table-fn">&#x0204e;</xref>, <xref rid="tf0040" ref-type="table-fn">#</xref></td><td/><td/><td align="char" rowspan="3">0.132</td></tr><tr><td>No</td><td>164 (69.5&#x000a0;%)</td><td>70 (61.4&#x000a0;%)</td></tr><tr><td>Yes</td><td>72 (30.5&#x000a0;%)</td><td>44 (38.6&#x000a0;%)</td></tr></tbody></table><table-wrap-foot><fn><p>Legend: MDD: Major Depressive Disorder.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tf0035"><label>&#x0204e;</label><p id="np0035">Data is shown as absolute (n) and relative (%).</p></fn></table-wrap-foot><table-wrap-foot><fn id="tf0040"><label>#</label><p id="np0040">Anxiety disorders include panic disorder, agoraphobia, social anxiety, specific phobia, generalized anxiety disorder, obsessive-compulsive disorder, and posttraumatic stress disorder.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="s0060"><label>3.3</label><title>Presence of psychiatric diagnosis according to the severity of COVID-19 symptoms</title><p id="p0130">When analyzing the psychiatric diagnosis only in individuals with COVID-19 and splitting them into two groups regarding the severity of COVID-19 symptoms (asymptomatic or presenting mild symptoms vs. individuals with moderate/severe symptoms), we found no difference between groups for current MDD (<italic>p</italic>&#x000a0;=&#x000a0;0.252), current suicide risk (<italic>p</italic>&#x000a0;=&#x000a0;1.000), and current anxiety disorder (<italic>p</italic>&#x000a0;=&#x000a0;0.644). (Data not shown).</p></sec><sec id="s0065"><label>3.4</label><title>The severity of psychological symptoms and levels of stress in individuals with COVID-19</title><p id="p0135"><xref rid="f0005" ref-type="fig">Fig. 1</xref> presents the severity of psychological symptoms and stress levels between cases and controls. <xref rid="f0005" ref-type="fig">Fig. 1</xref>A demonstrates a greater severity of depressive symptoms in individuals with COVID-19 (5.00 [IQR: 2.00&#x02013;8.00]) as compared to controls (3.50 [IQR: 1.00&#x02013;7.00], <italic>p</italic>&#x000a0;=&#x000a0;0.034). <xref rid="f0005" ref-type="fig">Fig. 1</xref>B shows no difference in the severity of insomnia symptoms between individuals with COVID-19 (1.00 [IQR: 0.00&#x02013;2.50]) as compared to controls (0.00 [IQR: 0.00&#x02013;2.00], <italic>p</italic>&#x000a0;=&#x000a0;0.118). <xref rid="f0005" ref-type="fig">Fig. 1</xref>C indicates no difference between individuals with COVID-19 (7.00 [IQR: 3.00&#x02013;11.25]) and controls (5.00 [IQR: 2.00&#x02013;11.00], <italic>p</italic>&#x000a0;=&#x000a0;0.109) regarding the severity of anxiety symptoms. <xref rid="f0005" ref-type="fig">Fig. 1</xref>D presents greater levels of stress in individuals with COVID-19 (21.50 [IQR: 12.00&#x02013;31.00]) as compared to controls (17.00 [IQR: 9.00&#x02013;29.00], <italic>p</italic>&#x000a0;=&#x000a0;0.020). Thus, our findings indicate that individuals with COVID-19 present a greater severity of depressive symptoms and stress levels as compared to individuals without COVID-19.<fig id="f0005"><label>Fig. 1</label><caption><p>Severity of psychological symptoms and stress levels between individuals with COVID-19 (cases) and individuals without COVID-19 (controls).</p><p>HAM-D: Hamilton Depression Rating Scale; HAM-A: Hamilton Anxiety Rating Scale. The lines show the median and Interquartile Range (IQR). <xref rid="f0005" ref-type="fig">Fig. 1</xref>A demonstrates a greater severity of depressive symptoms in individuals with COVID-19 (5.00 [IQR: 2.00&#x02013;8.00]) as compared to controls (3.50 [IQR: 1.00&#x02013;7.00], p&#x000a0;=&#x000a0;0.034). <xref rid="f0005" ref-type="fig">Fig. 1</xref>B reveals no difference in the severity of insomnia symptoms between individuals with COVID-19 (1.00 [IQR: 0.00&#x02013;2.50]) as compared to controls (0.00 [IQR: 0.00&#x02013;2.00], <italic>p</italic>&#x000a0;=&#x000a0;0.118). <xref rid="f0005" ref-type="fig">Fig. 1</xref>C indicates no difference between individuals with COVID-19 (7.00 [IQR: 3.00&#x02013;11.25]) and controls (5.00 [IQR: 2.00&#x02013;11.00], <italic>p</italic>&#x000a0;=&#x000a0;0.109) regarding the severity of anxiety symptoms. <xref rid="f0005" ref-type="fig">Fig. 1</xref>D shows greater levels of stress in individuals with COVID-19 (21.50 [IQR: 12.00&#x02013;31.00]) as compared to controls (17.00 [IQR: 9.00&#x02013;29.00], <italic>p</italic>&#x000a0;=&#x000a0;0.020).</p></caption><alt-text id="al0005">Fig. 1</alt-text><graphic xlink:href="gr1_lrg"/></fig></p></sec><sec id="s0070"><label>3.5</label><title>The severity of psychological symptoms and levels of stress according to the severity of COVID-19 symptoms</title><p id="p0140"><xref rid="f0010" ref-type="fig">Fig. 2</xref> demonstrates the severity of psychological symptoms and stress levels in individuals with COVID-19 according to the severity of COVID-19 symptoms. <xref rid="f0010" ref-type="fig">Fig. 2</xref>A reveals a greater severity of depressive symptoms in individuals with moderate/severe COVID-19 symptoms (8.00 [IQR: 4.25&#x02013;12.00]) as compared to individuals that are asymptomatic or presenting mild symptoms (4.00 [IQR: 1.00&#x02013;7.00], <italic>p</italic>&#x000a0;=&#x000a0;0.005). <xref rid="f0010" ref-type="fig">Fig. 2</xref>B indicates a greater severity of insomnia symptoms in individuals with moderate/severe COVID-19 symptoms (2.00 [IQR: 1.00&#x02013;4.00) as compared to individuals that are asymptomatic or presenting mild symptoms (0.00 [IQR: 0.00&#x02013;2.00], <italic>p</italic>&#x000a0;=&#x000a0;0.006). <xref rid="f0010" ref-type="fig">Fig. 2</xref>C shows that there is no difference between individuals with moderate/severe COVID-19 symptoms (9.00 [IQR: 3.00&#x02013;13.00]) and individuals that are asymptomatic or presenting mild symptoms (7.00 [IQR: 2.00&#x02013;10.50], <italic>p</italic>&#x000a0;=&#x000a0;0.235) regarding the severity of anxiety symptoms. <xref rid="f0010" ref-type="fig">Fig. 2</xref>D presents that there is no difference between individuals with moderate/severe COVID-19 symptoms (22.50 [IQR: 13.50&#x02013;35.25]) and individuals that are asymptomatic or presenting mild symptoms (21.00 [IQR: 12.00&#x02013;30.25], <italic>p</italic>&#x000a0;=&#x000a0;0.588) regarding the levels of stress. Thus, our findings show that individuals with moderate/severe COVID-19 symptoms present a greater severity of depressive and insomnia symptoms as compared to individuals that are asymptomatic or presenting mild COVID-19 symptoms.<fig id="f0010"><label>Fig. 2</label><caption><p>Severity of psychological symptoms and stress levels in individuals with COVID-19 according to the severity of COVID-19 symptoms.</p><p>HAM-D: Hamilton Depression Rating Scale; HAM-A: Hamilton Anxiety Rating Scale. The lines show the median and Interquartile Range (IQR). This figure only includes individuals with COVID-19, splitting them into two groups: (1) asymptomatic/mild COVID-19 symptoms and (2) individuals with moderate/severe COVID-19 symptoms. <xref rid="f0010" ref-type="fig">Fig. 2</xref>A shows a greater severity of depressive symptoms in individuals with moderate/severe COVID-19 symptoms (8.00 [IQR: 4.25&#x02013;12.00]) as compared to individuals that are asymptomatic or presenting mild symptoms (4.00 [IQR: 1.00&#x02013;7.00], <italic>p</italic>&#x000a0;=&#x000a0;0.005). <xref rid="f0010" ref-type="fig">Fig. 2</xref>B reveals a greater severity of insomnia symptoms in individuals with moderate/severe COVID-19 symptoms (2.00 [IQR: 1.00&#x02013;4.00) as compared to individuals that are asymptomatic or presenting mild symptoms (0.00 [IQR: 0.00&#x02013;2.00], <italic>p</italic>&#x000a0;=&#x000a0;0.006). <xref rid="f0010" ref-type="fig">Fig. 2</xref>C shows that there is no difference between individuals with moderate/severe COVID-19 symptoms (9.00 [IQR: 3.00&#x02013;13.00]) and individuals that are asymptomatic or presenting mild symptoms (7.00 [IQR: 2.00&#x02013;10.50], <italic>p</italic>&#x000a0;=&#x000a0;0.235) regarding the severity of anxiety symptoms. <xref rid="f0010" ref-type="fig">Fig. 2</xref>D demonstrates that there is no difference between individuals with moderate/severe COVID-19 symptoms (22.50 [IQR: 13.50&#x02013;35.25]) and individuals that are asymptomatic or presenting mild symptoms (21.00 [IQR: 12.00&#x02013;30.25], <italic>p</italic>&#x000a0;=&#x000a0;0.588) regarding the levels of stress.</p></caption><alt-text id="al0010">Fig. 2</alt-text><graphic xlink:href="gr2_lrg"/></fig></p></sec><sec id="s0075"><label>3.6</label><title>CRP levels and current psychiatric conditions in individuals committed with COVID-19</title><p id="p0145"><xref rid="f0015" ref-type="fig">Fig. 3</xref> demonstrates the association between COVID-19, current MDD, and CRP levels. <xref rid="f0015" ref-type="fig">Fig. 3</xref>A shows greater levels of CRP in individuals with a history of COVID-19 (1.72 [IQR: 0.77&#x02013;4.14] as compared to individuals without COVID-19 infection (1.19 [IQR: 0.56&#x02013;2.87], <italic>p</italic>&#x000a0;=&#x000a0;0.014). <xref rid="f0015" ref-type="fig">Fig. 3</xref>B only includes individuals with COVID-19, splitting them into two groups: (1) asymptomatic/mild COVID-19 symptoms and (2) individuals with moderate/severe COVID-19 symptoms. This figure reveals greater levels of CRP in individuals that had moderate/severe COVID-19 symptoms (2.62 [IQR: 1.60&#x02013;11.41]) as compared to individuals that displayed who were asymptomatic or presented with mild symptoms (1.48 [IQR: 0.57&#x02013;3.55], <italic>p</italic>&#x000a0;=&#x000a0;0.013). <xref rid="f0015" ref-type="fig">Fig. 3</xref>C shows that individuals with COVID-19 without current MDD had greater CRP levels (1.50 [IQR: 0.62&#x02013;3.55]) compared to individuals without both COVID-19 and current MDD (1.15 [IQR: 0.50&#x02013;2.52], <italic>p</italic>&#x000a0;=&#x000a0;0.047). Moreover, the figure indicates that individuals with COVID-19 and current MDD had greater CRP levels (3.21 [IQR: 1.89&#x02013;12.98]) as compared to individuals with COVID-19 without current MDD (1.50 [IQR: 0.62&#x02013;3.55], <italic>p</italic>&#x000a0;=&#x000a0;0.014) and as compared to individuals without both COVID-19 and MDD (1.15 [IQR: 0.50&#x02013;2.52], <italic>p</italic>&#x000a0;=&#x000a0;0.001). In addition, individuals without COVID-19 with current MDD presented greater CRP levels (1.58 [IQR: 0.84&#x02013;6.41]) as compared to individuals without both COVID-19 and MDD (1.15 [IQR: 0.50&#x02013;2.52], p&#x000a0;=&#x000a0;0.014). <xref rid="f0015" ref-type="fig">Fig. 3</xref>D displays that individuals with COVID-19 without anxiety disorders presented greater CRP levels (1.75 [IQR: 0.92&#x02013;4.43]) than individuals without both COVID-19 and anxiety disorders (1.16 [IQR: 0.51&#x02013;2.83], <italic>p</italic>&#x000a0;=&#x000a0;0.033). <xref rid="f0015" ref-type="fig">Fig. 3</xref>E shows that individuals with COVID-19 without suicide risk presented greater CRP levels (1.65 [IQR: 0.73&#x02013;4.33]) than individuals without both COVID-19 and suicide risk (1.19 [IQR: 0.52&#x02013;2.92], <italic>p</italic>&#x000a0;=&#x000a0;0.024).<fig id="f0015"><label>Fig. 3</label><caption><p>C-reactive protein, COVID-19, and psychiatric diagnosis.</p><p>CRP: C-reactive protein; MDD: Major Depressive Disorder; SR: Suicide Risk. The lines show the median and the Interquartile Range (IQR). <xref rid="f0015" ref-type="fig">Fig. 3</xref>A is showing greater levels of CRP in individuals with COVID-19 (1.72 [IQR: 0.77&#x02013;4.14] as compared to controls (1.19 [IQR: 0.56&#x02013;2.87], <italic>p</italic>&#x000a0;=&#x000a0;0.014). <xref rid="f0015" ref-type="fig">Fig. 3</xref>B only includes individuals with COVID-19, splitting them into two groups: (1) asymptomatic/mild COVID-19 symptoms and (2) individuals with moderate/severe COVID-19 symptoms. This figure illustrates greater levels of CRP in individuals with moderate/severe symptoms (2.62 [IQR: 1.60&#x02013;11.41]) as compared to individuals who were asymptomatic/mild symptoms (1.48 [IQR: 0.57&#x02013;3.55], <italic>p</italic>&#x000a0;=&#x000a0;0.013). <xref rid="f0015" ref-type="fig">Fig. 3</xref>C shows that individuals with COVID-19 without current MDD had greater CRP levels (1.50 [IQR: 0.62&#x02013;3.55]) compared to individuals without both COVID-19 and current MDD (1.15 [IQR: 0.50&#x02013;2.52], <italic>p</italic>&#x000a0;=&#x000a0;0.047). Moreover, the figure indicates that individuals with COVID-19 and current MDD had greater CRP levels (3.21 [IQR: 1.89&#x02013;12.98]) as compared to individuals with COVID-19 without current MDD (1.50 [IQR: 0.62&#x02013;3.55], p&#x000a0;=&#x000a0;0.014) and as compared to individuals without both COVID-19 and MDD (1.15 [IQR: 0.50&#x02013;2.52], <italic>p</italic>&#x000a0;=&#x000a0;0.001). In addition, individuals without COVID-19 with MDD presented greater CRP levels (1.58 [IQR: 0.84&#x02013;6.41]) as compared to individuals without both COVID-19 and MDD (1.15 [IQR: 0.50&#x02013;2.52], p&#x000a0;=&#x000a0;0.014). <xref rid="f0015" ref-type="fig">Fig. 3</xref>D reveals that individuals with COVID-19 without anxiety disorders presented greater CRP levels (1.75 [IQR: 0.92&#x02013;4.43]) than individuals without both COVID-19 and anxiety disorders (1.16 [IQR: 0.51&#x02013;2.83], <italic>p</italic>&#x000a0;=&#x000a0;0.033). <xref rid="f0015" ref-type="fig">Fig. 3</xref>E displays that individuals with COVID-19 without suicide risk presented greater CRP levels (1.65 [IQR: 0.73&#x02013;4.33]) than individuals without both COVID-19 and suicide risk (1.19 [IQR: 0.52&#x02013;2.92], <italic>p</italic>&#x000a0;=&#x000a0;0.024).</p></caption><alt-text id="al0015">Fig. 3</alt-text><graphic xlink:href="gr3_lrg"/></fig></p></sec><sec id="s0080"><label>3.7</label><title>The correlation between psychological symptoms, levels of stress, and CRP</title><p id="p0150"><xref rid="f0020" ref-type="fig">Fig. 4</xref> shows the correlation between stress levels and the severity of anxiety symptoms. <xref rid="f0020" ref-type="fig">Fig. 4</xref>A reveals a positive correlation between stress and the severity of anxiety symptoms in the total sample (Spearman <italic>r</italic>&#x000a0;=&#x000a0;0.765, <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001, <italic>n</italic>&#x000a0;=&#x000a0;338). <xref rid="f0020" ref-type="fig">Fig. 4</xref>B demonstrates a positive correlation between stress and the severity of anxiety symptoms in individuals with COVID-19 (Spearman <italic>r</italic>&#x000a0;=&#x000a0;0.747, p&#x000a0;&#x0003c;&#x000a0;0.001, <italic>n</italic>&#x000a0;=&#x000a0;110). <xref rid="f0020" ref-type="fig">Fig. 4</xref>C discloses a positive correlation between stress and the severity of anxiety symptoms in individuals without COVID-19 (Spearman <italic>r</italic>&#x000a0;=&#x000a0;0.764, <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001, <italic>n</italic>&#x000a0;=&#x000a0;228). Thus, the greater the stress levels, greater the severity of anxiety symptoms in both cases and controls.<fig id="f0020"><label>Fig. 4</label><caption><p>Correlation between stress and severity of anxiety symptoms.</p><p>HAM-A: Hamilton Anxiety Rating Scale. <xref rid="f0020" ref-type="fig">Fig. 4</xref>A displays a positive correlation between stress and the severity of anxiety symptoms in the total sample (Spearman <italic>r</italic>&#x000a0;=&#x000a0;0.765, <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001, <italic>n</italic>&#x000a0;=&#x000a0;338). <xref rid="f0020" ref-type="fig">Fig. 4</xref>B shows a positive correlation between stress and the severity of anxiety symptoms in individuals with COVID-19 (Spearman <italic>r</italic>&#x000a0;=&#x000a0;0.747, p&#x000a0;&#x0003c;&#x000a0;0.001, <italic>n</italic>&#x000a0;=&#x000a0;110). <xref rid="f0020" ref-type="fig">Fig. 4</xref>C demonstrates a positive correlation between stress and the severity of anxiety symptoms in individuals without COVID-19 (Spearman <italic>r</italic>&#x000a0;=&#x000a0;0.764, p&#x000a0;&#x0003c;&#x000a0;0.001, <italic>n</italic>&#x000a0;=&#x000a0;228).</p></caption><alt-text id="al0020">Fig. 4</alt-text><graphic xlink:href="gr4_lrg"/></fig></p><p id="p0155"><xref rid="f0025" ref-type="fig">Fig. 5</xref> shows the correlation between stress levels and the severity of depressive symptoms. <xref rid="f0025" ref-type="fig">Fig. 5</xref>A demonstrates a positive correlation between stress and the severity of depressive symptoms in the total sample (Spearman <italic>r</italic>&#x000a0;=&#x000a0;0.663, <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001, <italic>n</italic>&#x000a0;=&#x000a0;323). <xref rid="f0025" ref-type="fig">Fig. 5</xref>B indicates a positive correlation between stress and the severity of depressive symptoms in individuals with COVID-19 (Spearman <italic>r</italic>&#x000a0;=&#x000a0;0.716, p&#x000a0;&#x0003c;&#x000a0;0.001, <italic>n</italic>&#x000a0;=&#x000a0;100). <xref rid="f0025" ref-type="fig">Fig. 5</xref>C shows a positive correlation between stress and the severity of depressive symptoms in individuals without COVID-19 (Spearman <italic>r</italic>&#x000a0;=&#x000a0;0.623, p&#x000a0;&#x0003c;&#x000a0;0.001, <italic>n</italic>&#x000a0;=&#x000a0;223). Thus, the greater the stress levels, greater the severity of depressive symptoms in both cases and controls.<fig id="f0025"><label>Fig. 5</label><caption><p>Correlation between stress and severity of depressive symptoms.</p><p>HAM-D: Hamilton Depression Rating Scale. <xref rid="f0025" ref-type="fig">Fig. 5</xref>A displays a positive correlation between stress and the severity of depressive symptoms in the total sample (Spearman <italic>r</italic>&#x000a0;=&#x000a0;0.663, p&#x000a0;&#x0003c;&#x000a0;0.001, <italic>n</italic>&#x000a0;=&#x000a0;323). <xref rid="f0025" ref-type="fig">Fig. 5</xref>B confirms a positive correlation between stress and the severity of depressive symptoms in individuals with COVID-19 (Spearman <italic>r</italic>&#x000a0;=&#x000a0;0.716, p&#x000a0;&#x0003c;&#x000a0;0.001, <italic>n</italic>&#x000a0;=&#x000a0;100). <xref rid="f0025" ref-type="fig">Fig. 5</xref>C reveals a positive correlation between stress and the severity of depressive symptoms in individuals without COVID-19 (Spearman <italic>r</italic>&#x000a0;=&#x000a0;0.623, p&#x000a0;&#x0003c;&#x000a0;0.001, <italic>n</italic>&#x000a0;=&#x000a0;223).</p></caption><alt-text id="al0025">Fig. 5</alt-text><graphic xlink:href="gr5_lrg"/></fig></p><p id="p0160"><xref rid="f0030" ref-type="fig">Fig. 6</xref> reveals the correlation between stress levels and the severity of insomnia symptoms. <xref rid="f0030" ref-type="fig">Fig. 6</xref>A demonstrates a positive correlation between stress and the severity of insomnia symptoms in the total sample (Spearman <italic>r</italic>&#x000a0;=&#x000a0;0.389, p&#x000a0;&#x0003c;&#x000a0;0.001, <italic>n</italic>&#x000a0;=&#x000a0;338). <xref rid="f0030" ref-type="fig">Fig. 6</xref>B indicates a positive correlation between stress and the severity of insomnia symptoms in individuals with COVID-19 (Spearman <italic>r</italic>&#x000a0;=&#x000a0;0.496, p&#x000a0;&#x0003c;&#x000a0;0.001, <italic>n</italic>&#x000a0;=&#x000a0;109). <xref rid="f0030" ref-type="fig">Fig. 6</xref>C illustrates a positive correlation between stress and the severity of insomnia symptoms in individuals without COVID-19 (Spearman <italic>r</italic>&#x000a0;=&#x000a0;0.327, p&#x000a0;&#x0003c;&#x000a0;0.001, <italic>n</italic>&#x000a0;=&#x000a0;229). Thus, the greater the stress levels, greater the severity of insomnia symptoms in both cases and controls.<fig id="f0030"><label>Fig. 6</label><caption><p>Correlation between stress and severity of insomnia.</p><p><xref rid="f0030" ref-type="fig">Fig. 6</xref>A shows a positive correlation between stress and the severity of insomnia symptoms in the total sample (Spearman <italic>r</italic>&#x000a0;=&#x000a0;0.389, p&#x000a0;&#x0003c;&#x000a0;0.001, n&#x000a0;=&#x000a0;338). <xref rid="f0030" ref-type="fig">Fig. 6</xref>B displays a positive correlation between stress and the severity of insomnia symptoms in individuals with COVID-19 (Spearman <italic>r</italic>&#x000a0;=&#x000a0;0.496, p&#x000a0;&#x0003c;&#x000a0;0.001, <italic>n</italic>&#x000a0;=&#x000a0;109). <xref rid="f0030" ref-type="fig">Fig. 6</xref>C indicates a positive correlation between stress and the severity of insomnia symptoms in individuals without COVID-19 (Spearman <italic>r</italic>&#x000a0;=&#x000a0;0.327, p&#x000a0;&#x0003c;&#x000a0;0.001, <italic>n</italic>&#x000a0;=&#x000a0;229).</p></caption><alt-text id="al0030">Fig. 6</alt-text><graphic xlink:href="gr6_lrg"/></fig></p><p id="p0165"><xref rid="f0035" ref-type="fig">Fig. 7</xref> explains the correlation between CRP levels and the severity of depressive symptoms. <xref rid="f0035" ref-type="fig">Fig. 7</xref>A elucidates a positive correlation between CRP levels and the severity of depressive symptoms in the total sample (Spearman <italic>r</italic>&#x000a0;=&#x000a0;0.177, <italic>p</italic>&#x000a0;=&#x000a0;0.002, <italic>n</italic>&#x000a0;=&#x000a0;315). <xref rid="f0035" ref-type="fig">Fig. 7</xref>B shows a positive correlation between CRP levels and the severity of depressive symptoms in individuals with COVID-19 (Spearman <italic>r</italic>&#x000a0;=&#x000a0;0.216, <italic>p</italic>&#x000a0;=&#x000a0;0.035, <italic>n</italic>&#x000a0;=&#x000a0;96). <xref rid="f0035" ref-type="fig">Fig. 7</xref>C reveals a positive correlation between CRP levels and the severity of depressive symptoms in individuals without COVID-19 (Spearman <italic>r</italic>&#x000a0;=&#x000a0;0.141, <italic>p</italic>&#x000a0;=&#x000a0;0.037, <italic>n</italic>&#x000a0;=&#x000a0;219). Thus, the greater the CRP levels, greater the severity of depressive symptoms in both cases and controls.<fig id="f0035"><label>Fig. 7</label><caption><p>Correlation between CRP levels and severity of depressive symptoms.</p><p>HAM-D: Hamilton Depression Rating Scale; CRP: C-reactive protein. <xref rid="f0035" ref-type="fig">Fig. 7</xref>A demonstrates a positive correlation between CRP levels and the severity of depressive symptoms in the total sample (Spearman <italic>r</italic>&#x000a0;=&#x000a0;0.177, <italic>p</italic>&#x000a0;=&#x000a0;0.002, <italic>n</italic>&#x000a0;=&#x000a0;315). <xref rid="f0035" ref-type="fig">Fig. 7</xref>B shows a positive correlation between CRP levels and the severity of depressive symptoms in individuals with COVID-19 (Spearman <italic>r</italic>&#x000a0;=&#x000a0;0.216, <italic>p</italic>&#x000a0;=&#x000a0;0.035, <italic>n</italic>&#x000a0;=&#x000a0;96). <xref rid="f0035" ref-type="fig">Fig. 7</xref>C reveals a positive correlation between CRP levels and the severity of depressive symptoms in individuals without COVID-19 (Spearman <italic>r</italic>&#x000a0;=&#x000a0;0.141, <italic>p</italic>&#x000a0;=&#x000a0;0.037, <italic>n</italic>&#x000a0;=&#x000a0;219).</p></caption><alt-text id="al0035">Fig. 7</alt-text><graphic xlink:href="gr7_lrg"/></fig></p><p id="p0170"><xref rid="f0040" ref-type="fig">Fig. 8</xref> demonstrates the correlation between CRP levels and the severity of anxiety symptoms. <xref rid="f0040" ref-type="fig">Fig. 8</xref>A illustrates a positive correlation between CRP levels and the severity of anxiety symptoms in the total sample (Spearman <italic>r</italic>&#x000a0;=&#x000a0;0.154, <italic>p</italic>&#x000a0;=&#x000a0;0.005, <italic>n</italic>&#x000a0;=&#x000a0;330). <xref rid="f0040" ref-type="fig">Fig. 8</xref>B indicates a positive correlation between CRP levels and the severity of anxiety symptoms in individuals with COVID-19 (Spearman <italic>r</italic>&#x000a0;=&#x000a0;0.232, <italic>p</italic>&#x000a0;=&#x000a0;0.016, <italic>n</italic>&#x000a0;=&#x000a0;107). <xref rid="f0040" ref-type="fig">Fig. 8</xref>C shows that the correlation between CRP levels and the severity of anxiety symptoms in individuals without COVID-19 is not statistically significant (Spearman <italic>r</italic>&#x000a0;=&#x000a0;0.104, <italic>p</italic>&#x000a0;=&#x000a0;0.123, <italic>n</italic>&#x000a0;=&#x000a0;223). Thus, the greater the CRP levels, greater the severity of anxiety symptoms in the total sample, and in individuals with COVID-19.<fig id="f0040"><label>Fig. 8</label><caption><p>Correlation between CRP levels and severity of anxiety symptoms.</p><p>HAM-A: Hamilton Anxiety Rating Scale; CRP: C-reactive protein. <xref rid="f0040" ref-type="fig">Fig. 8</xref>A illustrates a positive correlation between CRP levels and the severity of anxiety symptoms in the total sample (Spearman <italic>r</italic>&#x000a0;=&#x000a0;0.154, <italic>p</italic>&#x000a0;=&#x000a0;0.005, <italic>n</italic>&#x000a0;=&#x000a0;330). <xref rid="f0040" ref-type="fig">Fig. 8</xref>B shows a positive correlation between CRP levels and the severity of anxiety symptoms in individuals with COVID-19 (Spearman <italic>r</italic>&#x000a0;=&#x000a0;0.232, <italic>p</italic>&#x000a0;=&#x000a0;0.016, <italic>n</italic>&#x000a0;=&#x000a0;107). <xref rid="f0040" ref-type="fig">Fig. 8</xref>C demonstrates that the correlation between CRP levels and the severity of anxiety symptoms in individuals without COVID-19 is not statistically significant (Spearman <italic>r</italic>&#x000a0;=&#x000a0;0.104, <italic>p</italic>&#x000a0;=&#x000a0;0.123, <italic>n</italic>&#x000a0;=&#x000a0;223).</p></caption><alt-text id="al0040">Fig. 8</alt-text><graphic xlink:href="gr8_lrg"/></fig></p><p id="p0175"><xref rid="f0045" ref-type="fig">Fig. 9</xref> reveals the correlation between CRP levels and the severity of insomnia symptoms. <xref rid="f0045" ref-type="fig">Fig. 9</xref>A displays that the correlation between CRP levels and insomnia is not statistically significant in the total sample (Spearman <italic>r</italic>&#x000a0;=&#x000a0;0.059, <italic>p</italic>&#x000a0;=&#x000a0;0.283, n&#x000a0;=&#x000a0;330). <xref rid="f0045" ref-type="fig">Fig. 9</xref>B demonstrates that the correlation between CRP levels and insomnia is not statistically significant in individuals with COVID-19 (Spearman <italic>r</italic>&#x000a0;=&#x000a0;0.095, <italic>p</italic>&#x000a0;=&#x000a0;0.335, <italic>n</italic>&#x000a0;=&#x000a0;106). <xref rid="f0045" ref-type="fig">Fig. 9</xref>C displays that the correlation between CRP levels and insomnia is not statistically significant in individuals without COVID-19 (Spearman <italic>r</italic>&#x000a0;=&#x000a0;0.021, <italic>p</italic>&#x000a0;=&#x000a0;0.758, <italic>n</italic>&#x000a0;=&#x000a0;224).<fig id="f0045"><label>Fig. 9</label><caption><p>Correlation between CRP levels and severity of insomnia symptoms.</p><p>CRP: C-reactive protein. <xref rid="f0045" ref-type="fig">Fig. 9</xref>A shows that the correlation between CRP levels and insomnia is not statistically significant in the total sample (Spearman <italic>r</italic>&#x000a0;=&#x000a0;0.059, <italic>p</italic>&#x000a0;=&#x000a0;0.283, n&#x000a0;=&#x000a0;330). <xref rid="f0045" ref-type="fig">Fig. 9</xref>B reveals that the correlation between CRP levels and insomnia is not statistically significant in individuals with COVID-19 (Spearman <italic>r</italic>&#x000a0;=&#x000a0;0.095, <italic>p</italic>&#x000a0;=&#x000a0;0.335, <italic>n</italic>&#x000a0;=&#x000a0;106). <xref rid="f0045" ref-type="fig">Fig. 9</xref>C indicates that the correlation between CRP levels and insomnia is not statistically significant in individuals without COVID-19 (Spearman <italic>r</italic>&#x000a0;=&#x000a0;0.021, <italic>p</italic>&#x000a0;=&#x000a0;0.758, <italic>n</italic>&#x000a0;=&#x000a0;224).</p></caption><alt-text id="al0045">Fig. 9</alt-text><graphic xlink:href="gr9_lrg"/></fig></p><p id="p0180"><xref rid="f0050" ref-type="fig">Fig. 10</xref> illustrates the correlation between CRP levels and stress levels. <xref rid="f0050" ref-type="fig">Fig. 10</xref>A shows a positive correlation between CRP levels and stress levels in the total sample (Spearman <italic>r</italic>&#x000a0;=&#x000a0;0.163, <italic>p</italic>&#x000a0;=&#x000a0;0.003, <italic>n</italic>&#x000a0;=&#x000a0;326). <xref rid="f0050" ref-type="fig">Fig. 10</xref>B is showing a positive correlation between CRP levels stress levels in individuals with COVID-19 (Spearman <italic>r</italic>&#x000a0;=&#x000a0;0.215, <italic>p</italic>&#x000a0;=&#x000a0;0.029, <italic>n</italic>&#x000a0;=&#x000a0;103). <xref rid="f0050" ref-type="fig">Fig. 10</xref>C demonstrates that the correlation between CRP levels and stress levels in individuals without COVID-19 is not statistically significant (Spearman <italic>r</italic>&#x000a0;=&#x000a0;0.113, <italic>p</italic>&#x000a0;=&#x000a0;0.093, n&#x000a0;=&#x000a0;223). Thus, the greater the CRP levels, greater the levels of stress in the total sample, and in individuals with COVID-19.<fig id="f0050"><label>Fig. 10</label><caption><p>Correlation between CRP and stress levels.</p><p>CRP: C-reactive protein. <xref rid="f0050" ref-type="fig">Fig. 10</xref>A displays a positive correlation between CRP levels and stress levels in the total sample (Spearman <italic>r</italic>&#x000a0;=&#x000a0;0.163, <italic>p</italic>&#x000a0;=&#x000a0;0.003, <italic>n</italic>&#x000a0;=&#x000a0;326). <xref rid="f0050" ref-type="fig">Fig. 10</xref>B shows a positive correlation between CRP levels stress levels in individuals with COVID-19 (Spearman <italic>r</italic>&#x000a0;=&#x000a0;0.215, <italic>p</italic>&#x000a0;=&#x000a0;0.029, <italic>n</italic>&#x000a0;=&#x000a0;103). <xref rid="f0050" ref-type="fig">Fig. 10</xref>C indicates that the correlation between CRP levels and stress levels in individuals without COVID-19 is not statistically significant (Spearman <italic>r</italic>&#x000a0;=&#x000a0;0.113, <italic>p</italic>&#x000a0;=&#x000a0;0.093, n&#x000a0;=&#x000a0;223).</p></caption><alt-text id="al0050">Fig. 10</alt-text><graphic xlink:href="gr10_lrg"/></fig></p></sec></sec><sec id="s0085"><label>4</label><title>Discussion</title><p id="p0185">Our study demonstrated that although individuals that had COVID-19 do not present significant higher rates of common mental disorders (MDD or anxiety), they already present greater severity of depressive symptoms, stress levels, and higher CRP levels than individuals that did not experience COVID-19 infection. In addition, among individuals that had COVID-19, those that showed moderate/severe COVID-19 symptoms presented greater severity of depressive and insomnia symptoms and more elevated CRP levels than those with mild COVID-19 symptoms or that were asymptomatic. Interestingly, individuals with both MDD and a COVID-19 history had increased CRP levels compared to those that had COVID-19 but not current MDD. Moreover, we found that the greater the stress levels, the greater the severity of depressive, anxiety, and insomnia symptoms in the total sample, as well as, in the cases and controls when assessed separately. Finally, our findings showed that the greater the CRP levels, the greater the severity of depressive symptoms in both cases and controls, and interestingly, the greater the CRP levels, the greater the severity of anxiety symptoms, and stress levels, but only in individuals with COVID-19.</p><p id="p0190">The psychiatric consequences of COVID-19 infection have been extensively discussed, and a recent systematic review and meta-analysis summarized the current literature showing that depression was the most prevalent psychiatric condition among COVID-19 survivors, affecting 18.3&#x000a0;% of the individuals (<xref rid="bb0195" ref-type="bibr">Zeng et al., 2022</xref>). This indicates that depression is a common consequence of COVID-19 infection; however, we should interpret this data in the light of some limitations: (i) the meta-analysis does not have a control group of individuals without COVID-19. Thus, it is unclear whether COVID-19 survivors have an increased prevalence of depression compared to individuals without COVID-19, and (ii) the majority of the studies included evaluated psychiatric symptoms using self-reported assessments, which may overestimate the depression rate. A recent large prospective cohort study including 1164 COVID-19 survivors and 1164 matched controls showed that COVID-19 survivors had an increased prevalence of self-reported depression/anxiety (26&#x000a0;%) as compared to individuals without COVID-19 (5&#x000a0;%, <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.0001) at the 12-month follow-up (<xref rid="bb0070" ref-type="bibr">Huang et al., 2021</xref>). These findings align with the present study's findings because although we did not find differences between individuals with a history of COVID-19 and controls regarding the presence of psychiatric diagnosis assessed through a clinical interview, individuals with COVID-19 reported greater severity of depressive symptoms as compared to controls.</p><p id="p0195">The biological underpinnings for this psychiatric consequence following COVID-19 are an urgent need because this is critical for the development of treatment and prevention of the poor outcomes after acute SARS-CoV-2 infection. A recent review showed that CRP is a potential biomarker for post-COVID depression that deserves investigation (<xref rid="bb0100" ref-type="bibr">Lorkiewicz and Waszkiewicz, 2021</xref>). Another study found that individuals with COVID-19 and an indication of depression, as assessed through a self-reported measure, presented greater CRP levels than individuals with COVID-19 without an indication of depression (<xref rid="bb0190" ref-type="bibr">Yuan et al., 2020</xref>). Our results confirmed these findings showing that individuals with COVID-19 and current MDD, assessed through a standardized clinical interview, presented greater CRP levels than individuals with COVID-19 without current MDD.</p><p id="p0200">Additionally, one study found that individuals who self-reported experiencing severe COVID-19 symptoms were more likely to display clinically relevant depression than those who self-reported a mild COVID-19 infection (<xref rid="bb0070" ref-type="bibr">Huang et al., 2021</xref>). A recent meta-analysis showed a near four-fold higher risk of poor outcomes (including greater severity of COVID-19 symptoms) in COVID-19 patients with elevated CRP (<xref rid="bb0105" ref-type="bibr">Malik et al., 2021</xref>). Our findings are in line with the previous literature, as we also showed that among individuals with COVID-19, those with moderate/severe COVID-19 symptoms presented greater severity of depressive and insomnia symptoms, as well as greater CRP levels compared to those with asymptomatic/mild COVID-19 symptoms. The increased CRP levels in individuals with moderate/severe COVID-19 may be a potential explanation for why these individuals also present a greater severity of depressive and insomnia symptoms. Altogether, our findings are clinically relevant because they show that COVID-19 may negatively impact the mental health of individuals in COVID-19 survivors. This may be explained by the greater levels of inflammation, which may inform therapeutic strategies to prevent or improve these adverse outcomes.</p><p id="p0205">Our findings should be interpreted considering some limitations. First, we cannot infer causality because this is a cross-sectional study. Future longitudinal studies are encouraged to show whether COVID-19 increases the risk of developing mental health disorders. Second, the majority of our COVID-19 sample was asymptomatic or had mild symptoms, which may limit the generalizability of our findings for moderate/severe cases. Finally, in this study, we only focused on one clinically relevant biomarker in the field of infection and mental health. Thus, the investigation of other biomarkers in the field is needed. Despite these limitations, our study has many strengths. First, our study assessed psychiatric diagnosis using a standardized clinical interview, which is a gold-standard assessment for psychiatric diagnosis in research; while the most extensive literature has been focusing on screening tools that only provide information about the presence of an indicative for common mental disorders, instead of a clinical diagnosis. Second, our study design allowed us to assess individuals with COVID-19 in a short window of 4 to 6&#x000a0;weeks of their infection, which controls for the impact of the duration of the infection on the outcomes studied. Finally, the beginning of the study was very timely, as it started in September 2020.</p><p id="p0210">In conclusion, our findings showed that the COVID-19 is associated with greater severity of depressive symptoms, stress, and CRP levels. Further, CRP levels were more significantly increased in individuals with MDD and COVID-19 than in individuals with COVID-19 without MDD, indicating that CRP is a potential biomarker to explain post-COVID depression. These results could contribute to the design of future prospective cohort studies aimed at assessing the development of common mental disorders after COVID-19 infection, as well as the biological underpinnings for the psychiatric conditions due to COVID-19 infection.</p><p id="p0215">The following is the supplementary data related to this article.<supplementary-material content-type="local-data" id="ec0005"><caption><title>Table S1</title><p>Medications used to treat or prevent COVID-19 symptoms between cases and controls that self-reported the use of medication.</p></caption><media xlink:href="mmc1.docx"><alt-text>Table S1</alt-text></media></supplementary-material>
</p></sec><sec id="s0090"><title>CRediT authorship contribution statement</title><p id="p0225">Conceptualization, <bold>GZR, ZMI, JQ, TAC, and LBC</bold>; Formal analysis, <bold>TCA</bold>; Funding acquisition, <bold>GZR</bold>; Investigation and Methodology, <bold>RHS, JLF, COA, GA, APZP, LAB, MEMB, ALM, SJBS, CD, MEB, and MDB</bold>; Project administration, <bold>GZR and ZMI</bold>; Resources, <bold>GZR, LBC, and JQ</bold>; Supervision; <bold>GZR</bold>; Roles/Writing - original draft, <bold>TAC and GZR</bold>; Writing - review &#x00026; editing, <bold>GZR, TB, and RM.</bold>
</p></sec><sec id="s0095"><title>Role of funding</title><p id="p0230">None.</p></sec><sec sec-type="COI-statement"><title>Conflict of interest</title><p id="p0235">The authors report no biomedical financial interests or potential conflicts of interest.</p></sec></body><back><ref-list id="bi0005"><title>References</title><ref id="bb0005"><element-citation publication-type="journal" id="rf202303100011522923"><person-group person-group-type="author"><name><surname>Amorim</surname><given-names>P.</given-names></name></person-group><article-title>Mini international neuropsychiatric interview (MINI): valida&#x000e7;&#x000e3;o de entrevista breve Para diagn&#x000f3;stico de transtornos mentais</article-title><source>Rev. Bras. Psiquiatr.</source><volume>22</volume><year>2000</year><fpage>106</fpage><lpage>121</lpage></element-citation></ref><ref id="bb0010"><element-citation publication-type="journal" id="rf202303100012094732"><person-group person-group-type="author"><name><surname>Bertollo</surname><given-names>A.</given-names></name><name><surname>Grolli</surname><given-names>R.</given-names></name><name><surname>Plissari</surname><given-names>M.</given-names></name><name><surname>Gasparin</surname><given-names>V.</given-names></name><name><surname>Quevedo</surname><given-names>J.</given-names></name><name><surname>R&#x000e9;us</surname><given-names>G.</given-names></name><name><surname>Bagatini</surname><given-names>M.</given-names></name><name><surname>Ign&#x000e1;cio</surname><given-names>Z.</given-names></name></person-group><article-title>Stress and serum cortisol levels in major depressive disorder: a cross-sectional study</article-title><source>AIMS Neurosci.</source><year>2020</year><pub-id pub-id-type="doi">10.3934/Neuroscience.2020028</pub-id></element-citation></ref><ref id="bb0015"><element-citation publication-type="journal" id="rf202303100019040347"><person-group person-group-type="author"><name><surname>Carlessi</surname><given-names>A.S.</given-names></name><name><surname>Borba</surname><given-names>L.A.</given-names></name><name><surname>Zugno</surname><given-names>A.I.</given-names></name><name><surname>Quevedo</surname><given-names>J.</given-names></name><name><surname>R&#x000e9;us</surname><given-names>G.Z.</given-names></name></person-group><article-title>Gut microbiota&#x02013;brain axis in depression: the role of neuroinflammation</article-title><source>Eur. J. Neurosci.</source><volume>53</volume><year>2021</year><fpage>222</fpage><lpage>235</lpage><pub-id pub-id-type="doi">10.1111/EJN.14631</pub-id><pub-id pub-id-type="pmid">31785168</pub-id></element-citation></ref><ref id="bb0020"><element-citation publication-type="journal" id="rf202303100019049847"><person-group person-group-type="author"><name><surname>da Silva</surname><given-names>G.B.</given-names></name><name><surname>Manica</surname><given-names>D.</given-names></name><name><surname>da Silva</surname><given-names>A.P.</given-names></name><name><surname>Kosvoski</surname><given-names>G.C.</given-names></name><name><surname>Hanauer</surname><given-names>M.</given-names></name><name><surname>Assmann</surname><given-names>C.E.</given-names></name><name><surname>Sim&#x000f5;es</surname><given-names>J.L.B.</given-names></name><name><surname>Pillat</surname><given-names>M.M.</given-names></name><name><surname>de Lara</surname><given-names>J.D.</given-names></name><name><surname>Marafon</surname><given-names>F.</given-names></name><name><surname>Bertollo</surname><given-names>A.G.</given-names></name><name><surname>Mingoti</surname><given-names>M.E.D.</given-names></name><name><surname>Gavioli</surname><given-names>J.</given-names></name><name><surname>R&#x000e9;us</surname><given-names>G.Z.</given-names></name><name><surname>de Oliveira</surname><given-names>G.G.</given-names></name><name><surname>Ign&#x000e1;cio</surname><given-names>Z.M.</given-names></name><name><surname>Bagatini</surname><given-names>M.D.</given-names></name></person-group><article-title>High levels of extracellular ATP lead to different inflammatory responses in COVID-19 patients according to the severity</article-title><source>J. Mol. Med.</source><volume>100</volume><year>2022</year><fpage>645</fpage><lpage>663</lpage><pub-id pub-id-type="doi">10.1007/S00109-022-02185-4</pub-id><pub-id pub-id-type="pmid">35249135</pub-id></element-citation></ref><ref id="bb0025"><element-citation publication-type="journal" id="rf202303100019057117"><person-group person-group-type="author"><name><surname>da Silva Lopes</surname><given-names>L.</given-names></name><name><surname>Silva</surname><given-names>R.O.</given-names></name><name><surname>de Sousa Lima</surname><given-names>G.</given-names></name><name><surname>de Ara&#x000fa;jo Costa</surname><given-names>A.C.</given-names></name><name><surname>Barros</surname><given-names>D.F.</given-names></name><name><surname>Silva-N&#x000e9;to</surname><given-names>R.P.</given-names></name></person-group><article-title>Is there a common pathophysiological mechanism between COVID-19 and depression?</article-title><source>Acta Neurol. Belg.</source><volume>121</volume><year>2021</year><fpage>1117</fpage><lpage>1122</lpage><pub-id pub-id-type="doi">10.1007/S13760-021-01748-5</pub-id><pub-id pub-id-type="pmid">34327666</pub-id></element-citation></ref><ref id="bb0030"><element-citation publication-type="book" id="rf202303100012236091"><person-group person-group-type="author"><name><surname>Derogatis</surname><given-names>L.R.</given-names></name></person-group><part-title>SCL-90-R: symptom checklist-90-R: administration, scoring &#x00026; procedures manual</part-title><source>Scoring, and Procedures Manual</source><year>1994</year></element-citation></ref><ref id="bb0035"><element-citation publication-type="journal" id="rf202303100012259171"><person-group person-group-type="author"><name><surname>Douaud</surname><given-names>G.</given-names></name><name><surname>Lee</surname><given-names>S.</given-names></name><name><surname>Alfaro-Almagro</surname><given-names>F.</given-names></name></person-group><article-title>SARS-CoV-2 is associated with changes in brain structure in UK biobank</article-title><source>Nature</source><year>2022</year><pub-id pub-id-type="doi">10.1038/s41586-022-04569-5</pub-id></element-citation></ref><ref id="bb0065"><element-citation publication-type="book" id="rf202303132050275490"><person-group person-group-type="author"><name><surname>Gorenstein</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>Y-P.</given-names></name><name><surname>Hungerb&#x000fc;hler</surname><given-names>I.</given-names></name></person-group><part-title>Instrumentos de avalia&#x000e7;&#x000e3;o em sa&#x000fa;de mental</part-title><year>2016</year><publisher-name>Artmed</publisher-name><publisher-loc>Porto Alegre</publisher-loc></element-citation></ref><ref id="bb0040"><element-citation publication-type="journal" id="rf202303100019064997"><person-group person-group-type="author"><name><surname>Grolli</surname><given-names>R.E.</given-names></name><name><surname>Mingoti</surname><given-names>M.E.D.</given-names></name><name><surname>Bertollo</surname><given-names>A.G.</given-names></name><name><surname>Luzardo</surname><given-names>A.R.</given-names></name><name><surname>Quevedo</surname><given-names>J.</given-names></name><name><surname>R&#x000e9;us</surname><given-names>G.Z.</given-names></name><name><surname>Ign&#x000e1;cio</surname><given-names>Z.M.</given-names></name></person-group><article-title>Impact of COVID-19 in the mental health in elderly: psychological and biological updates</article-title><source>Mol. Neurobiol.</source><volume>58</volume><year>2021</year><fpage>1905</fpage><lpage>1916</lpage><pub-id pub-id-type="doi">10.1007/S12035-020-02249-X</pub-id><pub-id pub-id-type="pmid">33404981</pub-id></element-citation></ref><ref id="bb0045"><element-citation publication-type="journal" id="rf202303100012268760"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>Q.</given-names></name><name><surname>Zheng</surname><given-names>Y.</given-names></name><name><surname>Shi</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>G.</given-names></name></person-group><article-title>Immediate psychological distress in quarantined patients with COVID-19 and its association with peripheral inflammation: a mixed-method study</article-title><source>Brain Behav. Immun.</source><volume>88</volume><year>2020</year><fpage>17</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1016/j.bbi.2020.05.038</pub-id><pub-id pub-id-type="pmid">32416290</pub-id></element-citation></ref><ref id="bb0050"><element-citation publication-type="journal" id="rf202303100019262897"><person-group person-group-type="author"><name><surname>Hamilton</surname><given-names>M.</given-names></name></person-group><article-title>Development of a rating scale for primary depressive illness</article-title><source>Br. J. Soc. Clin. Psychol.</source><volume>6</volume><year>1967</year><fpage>278</fpage><lpage>296</lpage><pub-id pub-id-type="doi">10.1111/J.2044-8260.1967.TB00530.X</pub-id><pub-id pub-id-type="pmid">6080235</pub-id></element-citation></ref><ref id="bb0055"><element-citation publication-type="journal" id="rf202303100019274637"><person-group person-group-type="author"><name><surname>Hamilton</surname><given-names>M.</given-names></name></person-group><article-title>The assessment of anxiety states by rating</article-title><source>Br. J. Med. Psychol.</source><year>1959</year><pub-id pub-id-type="doi">10.1111/j.2044-8341.1959.tb00467.x</pub-id></element-citation></ref><ref id="bb0060"><element-citation publication-type="journal" id="rf202303100019282777"><person-group person-group-type="author"><name><surname>He</surname><given-names>Y.</given-names></name><name><surname>Bai</surname><given-names>X.</given-names></name><name><surname>Zhu</surname><given-names>T.</given-names></name><name><surname>Huang</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name></person-group><article-title>What can the neurological manifestations of COVID-19 tell us: a meta-analysis</article-title><source>J. Transl. Med.</source><volume>19</volume><year>2021</year><pub-id pub-id-type="doi">10.1186/S12967-021-03039-2</pub-id></element-citation></ref><ref id="bb0070"><element-citation publication-type="journal" id="rf202303100012299380"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>L.</given-names></name><name><surname>Yao</surname><given-names>Q.</given-names></name><name><surname>Gu</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Ren</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Hu</surname><given-names>P.</given-names></name></person-group><article-title>1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study</article-title><source>Lancet</source><volume>398</volume><year>2021</year><fpage>747</fpage><lpage>748</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(21)01755-4</pub-id><pub-id pub-id-type="pmid">34454673</pub-id></element-citation></ref><ref id="bb0075"><element-citation publication-type="journal" id="rf202303100014022705"><person-group person-group-type="author"><name><surname>Iglesias-Gonz&#x000e1;lez</surname><given-names>M.</given-names></name><name><surname>Boigues</surname><given-names>M.</given-names></name><name><surname>Sanagustin</surname><given-names>D.</given-names></name></person-group><article-title>Association of serum interleukin-6 and C-reactive protein with depressive and adjustment disorders in COVID-19 inpatients</article-title><source>Brain Behav. Immunity-Health</source><volume>19</volume><year>2022</year><object-id pub-id-type="publisher-id">100405</object-id><pub-id pub-id-type="doi">10.1016/j.bbih.2021.100405</pub-id></element-citation></ref><ref id="bb0080"><element-citation publication-type="journal" id="rf202303100014113584"><person-group person-group-type="author"><name><surname>Klaser</surname><given-names>K.</given-names></name><name><surname>Thompson</surname><given-names>E.</given-names></name><name><surname>Nguyen</surname><given-names>L.</given-names></name></person-group><article-title>Anxiety and depression symptoms after COVID-19 infection: results from the COVID symptom study app</article-title><source>J. Neurol. Neurosurg. Psychiatry</source><volume>92</volume><year>2021</year><fpage>1254</fpage><lpage>1258</lpage><pub-id pub-id-type="pmid">34583944</pub-id></element-citation></ref><ref id="bb0085"><element-citation publication-type="journal" id="rf202303100019290307"><person-group person-group-type="author"><name><surname>Kuhlmann</surname><given-names>C.R.W.</given-names></name><name><surname>Librizzi</surname><given-names>L.</given-names></name><name><surname>Closhen</surname><given-names>D.</given-names></name><name><surname>Pflanzner</surname><given-names>T.</given-names></name><name><surname>Lessmann</surname><given-names>V.</given-names></name><name><surname>Pietrzik</surname><given-names>C.U.</given-names></name><name><surname>de Curtis</surname><given-names>M.</given-names></name><name><surname>Luhmann</surname><given-names>H.J.</given-names></name></person-group><article-title>Mechanisms of C-reactive protein-induced blood-brain barrier disruption</article-title><source>Stroke</source><volume>40</volume><year>2009</year><fpage>1458</fpage><lpage>1466</lpage><pub-id pub-id-type="doi">10.1161/STROKEAHA.108.535930</pub-id><pub-id pub-id-type="pmid">19246692</pub-id></element-citation></ref><ref id="bb0090"><element-citation publication-type="book" id="rf202303100014251323"><person-group person-group-type="author"><name><surname>Lipp</surname><given-names>M.</given-names></name><name><surname>Guevara</surname><given-names>A.</given-names></name></person-group><source>Valida&#x000e7;&#x000e3;o emp&#x000ed;rica do Invent&#x000e1;rio de Sintomas de Stress (ISS). Valida&#x000e7;&#x000e3;o emp&#x000ed;rica do Invent&#x000e1;rio de Sintomas de Stress</source><volume>11</volume><year>1994</year><fpage>43</fpage><lpage>49</lpage></element-citation></ref><ref id="bb0095"><element-citation publication-type="journal" id="rf202303100014403293"><person-group person-group-type="author"><name><surname>Liukkonen</surname><given-names>T.</given-names></name><name><surname>R&#x000e4;s&#x000e4;nen</surname><given-names>P.</given-names></name><name><surname>Jokelainen</surname><given-names>J.</given-names></name></person-group><article-title>The association between anxiety and C-reactive protein (CRP) levels: results from the northern Finland 1966 birth cohort study</article-title><source>Eur. Psychiatry</source><volume>26</volume><year>2011</year><fpage>363</fpage><lpage>369</lpage><pub-id pub-id-type="doi">10.1016/j.eurpsy.2011.02.001</pub-id><pub-id pub-id-type="pmid">21570260</pub-id></element-citation></ref><ref id="bb0100"><element-citation publication-type="journal" id="rf202303100019301017"><person-group person-group-type="author"><name><surname>Lorkiewicz</surname><given-names>P.</given-names></name><name><surname>Waszkiewicz</surname><given-names>N.</given-names></name></person-group><article-title>Biomarkers of post-COVID depression</article-title><source>J. Clin. Med.</source><volume>10</volume><year>2021</year><fpage>4142</fpage><pub-id pub-id-type="doi">10.3390/jcm10184142</pub-id><pub-id pub-id-type="pmid">34575258</pub-id></element-citation></ref><ref id="bb0105"><element-citation publication-type="journal" id="rf202303100015414749"><person-group person-group-type="author"><name><surname>Malik</surname><given-names>P.</given-names></name><name><surname>Patel</surname><given-names>U.</given-names></name><name><surname>Mehta</surname><given-names>D.</given-names></name><name><surname>Patel</surname><given-names>N.</given-names></name><name><surname>Kelkar</surname><given-names>R.</given-names></name></person-group><article-title>Biomarkers and outcomes of COVID-19 hospitalisations: systematic review and meta-analysis</article-title><source>BMJ Evid. Based Med.</source><volume>26</volume><year>2021</year><fpage>107</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1136/bmjebm-2020-111536</pub-id></element-citation></ref><ref id="bb0110"><element-citation publication-type="journal" id="rf202303100017162657"><person-group person-group-type="author"><name><surname>Manosso</surname><given-names>L.M.</given-names></name><name><surname>Arent</surname><given-names>C.O.</given-names></name><name><surname>Borba</surname><given-names>L.A.</given-names></name><name><surname>Ceretta</surname><given-names>L.B.</given-names></name><name><surname>Quevedo</surname><given-names>J.</given-names></name><name><surname>R&#x000e9;us</surname><given-names>G.Z.</given-names></name><name><surname>Giaroni</surname><given-names>C.</given-names></name></person-group><article-title>Microbiota-gut-brain communication in the SARS-CoV-2 infection</article-title><source>Cells</source><volume>10</volume><year>2021</year><fpage>1993</fpage><pub-id pub-id-type="doi">10.3390/cells10081993</pub-id><comment>2021, 10, 1993. Cells</comment><pub-id pub-id-type="pmid">34440767</pub-id></element-citation></ref><ref id="bb0115"><element-citation publication-type="journal" id="rf202303100015485969"><person-group person-group-type="author"><name><surname>Mazza</surname><given-names>M.</given-names></name><name><surname>Palladini</surname><given-names>M.</given-names></name><name><surname>de Lorenzo</surname><given-names>R.</given-names></name></person-group><article-title>Persistent psychopathology and neurocognitive impairment in COVID-19 survivors: effect of inflammatory biomarkers at three-month follow-up</article-title><source>Brain Behav. Immun.</source><volume>94</volume><year>2021</year><fpage>138</fpage><lpage>147</lpage><pub-id pub-id-type="doi">10.1016/j.bbi.2021.02.021</pub-id><pub-id pub-id-type="pmid">33639239</pub-id></element-citation></ref><ref id="bb0120"><element-citation publication-type="journal" id="rf202303100015505328"><person-group person-group-type="author"><name><surname>Misra</surname><given-names>S.</given-names></name><name><surname>Kolappa</surname><given-names>K.</given-names></name><name><surname>Prasad</surname><given-names>M.</given-names></name><name><surname>Radhakrishnan</surname><given-names>D.</given-names></name></person-group><article-title>Frequency of neurologic manifestations in COVID-19: a systematic review and meta-analysis</article-title><source>Neurology</source><volume>97</volume><year>2021</year><fpage>e2269</fpage><lpage>e2281</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000012930</pub-id><pub-id pub-id-type="pmid">34635561</pub-id></element-citation></ref><ref id="bb0125"><element-citation publication-type="journal" id="rf202303100015515078"><person-group person-group-type="author"><name><surname>Morales-Mu&#x000f1;oz</surname><given-names>I.</given-names></name><name><surname>Palmer</surname><given-names>E.</given-names></name><name><surname>Marwaha</surname><given-names>S.</given-names></name></person-group><article-title>Persistent childhood and adolescent anxiety and risk for psychosis: a longitudinal birth cohort study</article-title><source>Biol. Psychiatry</source><volume>92</volume><year>2022</year><fpage>275</fpage><lpage>282</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2021.12.003</pub-id><pub-id pub-id-type="pmid">35151465</pub-id></element-citation></ref><ref id="bb0130"><element-citation publication-type="journal" id="rf202303100019421017"><person-group person-group-type="author"><name><surname>Pezzini</surname><given-names>A.</given-names></name><name><surname>Padovani</surname><given-names>A.</given-names></name></person-group><article-title>Lifting the mask on neurological manifestations of COVID-19</article-title><source>Nat. Rev. Neurol.</source><volume>16</volume><year>2020</year><fpage>636</fpage><lpage>644</lpage><pub-id pub-id-type="doi">10.1038/s41582-020-0398-3</pub-id><pub-id pub-id-type="pmid">32839585</pub-id></element-citation></ref><ref id="bb0135"><element-citation publication-type="journal" id="rf202303100019434177"><person-group person-group-type="author"><name><surname>Puelles</surname><given-names>V.G.</given-names></name><name><surname>L&#x000fc;tgehetmann</surname><given-names>M.</given-names></name><name><surname>Lindenmeyer</surname><given-names>M.T.</given-names></name><name><surname>Sperhake</surname><given-names>J.P.</given-names></name><name><surname>Wong</surname><given-names>M.N.</given-names></name><name><surname>Allweiss</surname><given-names>L.</given-names></name><name><surname>Chilla</surname><given-names>S.</given-names></name><name><surname>Heinemann</surname><given-names>A.</given-names></name><name><surname>Wanner</surname><given-names>N.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Braun</surname><given-names>F.</given-names></name><name><surname>Lu</surname><given-names>S.</given-names></name><name><surname>Pfefferle</surname><given-names>S.</given-names></name><name><surname>Schr&#x000f6;der</surname><given-names>A.S.</given-names></name><name><surname>Edler</surname><given-names>C.</given-names></name><name><surname>Gross</surname><given-names>O.</given-names></name><name><surname>Glatzel</surname><given-names>M.</given-names></name><name><surname>Wichmann</surname><given-names>D.</given-names></name><name><surname>Wiech</surname><given-names>T.</given-names></name><name><surname>Kluge</surname><given-names>S.</given-names></name><name><surname>Pueschel</surname><given-names>K.</given-names></name><name><surname>Aepfelbacher</surname><given-names>M.</given-names></name><name><surname>Huber</surname><given-names>T.B.</given-names></name></person-group><article-title>Multiorgan and renal tropism of SARS-CoV-2</article-title><source>N. Engl. J. Med.</source><volume>383</volume><year>2020</year><fpage>590</fpage><lpage>592</lpage><pub-id pub-id-type="doi">10.1056/NEJMC2011400</pub-id><pub-id pub-id-type="pmid">32402155</pub-id></element-citation></ref><ref id="bb0140"><element-citation publication-type="journal" id="rf202303100019443297"><person-group person-group-type="author"><name><surname>Rhally</surname><given-names>A.</given-names></name><name><surname>Griffa</surname><given-names>A.</given-names></name><name><surname>Kremer</surname><given-names>S.</given-names></name><name><surname>Uginet</surname><given-names>M.</given-names></name><name><surname>Breville</surname><given-names>G.</given-names></name><name><surname>Stancu</surname><given-names>P.</given-names></name><name><surname>Assal</surname><given-names>F.</given-names></name><name><surname>Lalive</surname><given-names>P.H.</given-names></name><name><surname>L&#x000f6;vblad</surname><given-names>K.O.</given-names></name><name><surname>Allali</surname><given-names>G.</given-names></name></person-group><article-title>C-reactive protein and white matter microstructural changes in COVID-19 patients with encephalopathy</article-title><source>J. Neural Transm.</source><volume>128</volume><year>2021</year><fpage>1899</fpage><lpage>1906</lpage><pub-id pub-id-type="doi">10.1007/S00702-021-02429-6</pub-id><pub-id pub-id-type="pmid">34709472</pub-id></element-citation></ref><ref id="bb0145"><element-citation publication-type="journal" id="rf202303100015526178"><person-group person-group-type="author"><name><surname>Song</surname><given-names>E.</given-names></name><name><surname>Zhang</surname><given-names>C.</given-names></name><name><surname>Israelow</surname><given-names>B.</given-names></name><name><surname>Lu-Culligan</surname><given-names>A.</given-names></name></person-group><article-title>Neuroinvasion of SARS-CoV-2 in human and mouse brain</article-title><source>J. Exp. Med.</source><volume>218</volume><year>2021</year><pub-id pub-id-type="doi">10.1084/jem.20202135</pub-id></element-citation></ref><ref id="bb0150"><element-citation publication-type="journal" id="rf202303100015535338"><person-group person-group-type="author"><name><surname>Song</surname><given-names>J.</given-names></name><name><surname>Lam</surname><given-names>S.</given-names></name><name><surname>Fan</surname><given-names>X.</given-names></name><name><surname>Cao</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>S.</given-names></name><name><surname>Tian</surname><given-names>H.</given-names></name></person-group><article-title>Omics-driven systems interrogation of metabolic dysregulation in COVID-19 pathogenesis</article-title><source>Cell Metab.</source><volume>32</volume><year>2020</year><fpage>188</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2020.06.016</pub-id><pub-id pub-id-type="pmid">32610096</pub-id></element-citation></ref><ref id="bb0155"><element-citation publication-type="book" id="rf202303100017375277"><person-group person-group-type="author"><name><surname>Tchounwou</surname><given-names>P.B.</given-names></name><name><surname>Zhang</surname><given-names>S.X.</given-names></name><name><surname>Chen</surname><given-names>R.Z.</given-names></name><name><surname>Xu</surname><given-names>W.</given-names></name><name><surname>Yin</surname><given-names>A.</given-names></name><name><surname>Dong</surname><given-names>R.K.</given-names></name><name><surname>Chen</surname><given-names>B.Z.</given-names></name><name><surname>Delios</surname><given-names>A.Y.</given-names></name><name><surname>Miller</surname><given-names>S.</given-names></name><name><surname>Mcintyre</surname><given-names>R.S.</given-names></name><name><surname>Ye</surname><given-names>W.</given-names></name><name><surname>Wan</surname><given-names>X.</given-names></name></person-group><source>A Systematic Review and Meta-analysis of Symptoms of Anxiety, Depression, and Insomnia in Spain in the COVID-19 Crisis. mdpi.com</source><year>2022</year><fpage>19</fpage><pub-id pub-id-type="doi">10.3390/ijerph19021018</pub-id></element-citation></ref><ref id="bb0160"><element-citation publication-type="journal" id="rf202303100016147008"><person-group person-group-type="author"><name><surname>Upthegrove</surname><given-names>R.</given-names></name><name><surname>Khandaker</surname><given-names>G.</given-names></name></person-group><article-title>Cytokines, oxidative stress and cellular markers of inflammation in schizophrenia</article-title><source>Neuroinflammation Schizophr.</source><volume>44</volume><year>2020</year><fpage>49</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1007/7854_2018_88</pub-id></element-citation></ref><ref id="bb0165"><element-citation publication-type="journal" id="rf202303100016273658"><person-group person-group-type="author"><name><surname>del Valle</surname><given-names>D.</given-names></name><name><surname>Kim-Schulze</surname><given-names>S.</given-names></name><name><surname>Huang</surname><given-names>H.</given-names></name></person-group><article-title>An inflammatory cytokine signature predicts COVID-19 severity and survival</article-title><source>Nat. Med.</source><volume>26</volume><year>2020</year><fpage>1636</fpage><lpage>1643</lpage><pub-id pub-id-type="doi">10.1038/s41591-020-1051-9</pub-id><pub-id pub-id-type="pmid">32839624</pub-id></element-citation></ref><ref id="bb0170"><element-citation publication-type="journal" id="rf202303100016283658"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Hu</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>M.</given-names></name></person-group><article-title>Early risk factors of the exacerbation of coronavirus disease 2019 pneumonia</article-title><source>J. Med. Virol.</source><volume>92</volume><year>2020</year><fpage>2593</fpage><lpage>2599</lpage><pub-id pub-id-type="doi">10.1002/jmv.26071</pub-id><pub-id pub-id-type="pmid">32470167</pub-id></element-citation></ref><ref id="bb0175"><element-citation publication-type="book" id="rf202303100017509797"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><part-title>Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19)</part-title><year>2020</year></element-citation></ref><ref id="bb0180"><element-citation publication-type="book" id="rf202303100018101497"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><part-title>WHO Coronavirus Disease (COVID-19) Dashboard</part-title><year>2020</year></element-citation></ref><ref id="bb0185"><element-citation publication-type="book" id="rf202303100019025477"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>Y.</given-names></name><name><surname>Du</surname><given-names>X.</given-names></name><name><surname>Lai</surname><given-names>L.</given-names></name><name><surname>Ren</surname><given-names>Z.</given-names></name><name><surname>geriatric</surname><given-names>H.L.-J.of</given-names></name></person-group><comment>undefined, 2019</comment><source>Prevalence of Depressive and Anxiety Symptoms Among Chinese Older Adults During the COVID-19 Pandemic: A Systematic Review and Meta-analysis. journals.sagepub.com</source><volume>2022</volume><year>2022</year><fpage>182</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1177/08919887221078556</pub-id></element-citation></ref><ref id="bb0190"><element-citation publication-type="journal" id="rf202303100016294558"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>B.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Cai</surname><given-names>X.</given-names></name><name><surname>Song</surname><given-names>S.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Hu</surname><given-names>X.</given-names></name></person-group><article-title>Correlation between immune response and self-reported depression during convalescence from COVID-19</article-title><source>Brain Behav. Immun.</source><volume>88</volume><year>2020</year><fpage>39</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1016/j.bbi.2020.05.062</pub-id><pub-id pub-id-type="pmid">32464158</pub-id></element-citation></ref><ref id="bb0195"><element-citation publication-type="journal" id="rf202303100016395667"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>N.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Yan</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Lu</surname><given-names>Q.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name></person-group><article-title>A systematic review and meta-analysis of long term physical and mental sequelae of COVID-19 pandemic: call for research priority and action</article-title><source>Mol. Psychiatry</source><year>2022</year><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1038/s41380-022-01614-7</pub-id></element-citation></ref><ref id="bb0200"><element-citation publication-type="journal" id="rf202303100016401517"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Tan</surname><given-names>Y.</given-names></name><name><surname>Ling</surname><given-names>Y.</given-names></name><name><surname>Lu</surname><given-names>G.</given-names></name><name><surname>Liu</surname><given-names>F.</given-names></name><name><surname>Yi</surname><given-names>Z.</given-names></name><name><surname>Jia</surname><given-names>X.</given-names></name><name><surname>Wu</surname><given-names>N.</given-names></name></person-group><article-title>Viral and host factors related to the clinical outcome of COVID-19</article-title><source>Nature</source><volume>583</volume><year>2020</year><fpage>437</fpage><lpage>440</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2355-0</pub-id><pub-id pub-id-type="pmid">32434211</pub-id></element-citation></ref><ref id="bb0205"><element-citation publication-type="journal" id="rf202303100016494198"><person-group person-group-type="author"><name><surname>Zubair</surname><given-names>A.</given-names></name><name><surname>McAlpine</surname><given-names>L.</given-names></name><name><surname>Gardin</surname><given-names>T.</given-names></name><name><surname>Farhadian</surname><given-names>S.</given-names></name></person-group><article-title>Neuropathogenesis and neurologic manifestations of the coronaviruses in the age of coronavirus disease 2019: a review</article-title><source>JAMA Neurol.</source><volume>77</volume><year>2020</year><fpage>1018</fpage><lpage>1027</lpage><pub-id pub-id-type="doi">10.1001/jamaneurol.2020.2065</pub-id><pub-id pub-id-type="pmid">32469387</pub-id></element-citation></ref></ref-list><ack id="ac0005"><title>Acknowledgments</title><p id="p0240">This research was supported by grants from <funding-source id="gts0005"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100003593</institution-id><institution>CNPq</institution></institution-wrap></funding-source> (GZR) &#x0201c;MCTIC/CNPq/FNDCT/MS/SCTIE/Decit No 07/2020&#x0201d;, FAPESC (GZR), and <funding-source id="gts0010"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100013360</institution-id><institution>UNESC</institution></institution-wrap></funding-source> (GZR, JQ, and LBC). We thank all the people who participated in this study. Our research team, for their help in recruiting the patients. The whole UNESC and Federal University of the Southern Frontier, includes interviewers, research scientists, volunteers, managers, receptionists, and drivers. GZR is a 2 CNPq Research Fellow. This research was also supported by grants from the <funding-source id="gts0015"><institution-wrap><institution-id institution-id-type="doi">10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source>/<funding-source id="gts0020"><institution-wrap><institution-id institution-id-type="doi">10.13039/100000049</institution-id><institution>National Institute on Aging</institution></institution-wrap></funding-source> (NIH/NIA grant 1RF1AG072491) and the <funding-source id="gts0025">Texas Alzheimer's Research and Care Consortium</funding-source> (TARCC) (RM and TB).</p></ack></back></article>
